Published in Trans R Soc Trop Med Hyg on April 01, 2002
Leishmania chagasi T-cell antigens identified through a double library screen. Infect Immun (2006) 0.83
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis (2008) 3.27
Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 2.56
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol (2002) 2.07
Combination therapy for visceral leishmaniasis. Lancet Infect Dis (2010) 1.96
Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis (2010) 1.90
Leishmania/HIV co-infections in the second decade. Indian J Med Res (2006) 1.73
Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev (2009) 1.45
Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev (2008) 1.35
PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J Clin Microbiol (2002) 1.33
Natural history of a visceral leishmaniasis outbreak in highland Ethiopia. Am J Trop Med Hyg (2009) 1.29
Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol (2006) 1.26
Risk factors for visceral leishmaniasis in a new epidemic site in Amhara Region, Ethiopia. Am J Trop Med Hyg (2009) 1.25
Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs (2009) 1.23
Population movement: a key factor in the epidemiology of neglected tropical diseases. Trop Med Int Health (2010) 1.16
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother (2003) 1.15
Risk factors for visceral Leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia. PLoS Negl Trop Dis (2013) 1.07
Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother (2004) 1.06
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis (2013) 1.03
Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis (2010) 1.02
Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis (2002) 1.01
Evaluation of two rK39 dipstick tests, direct agglutination test, and indirect fluorescent antibody test for diagnosis of visceral leishmaniasis in a new epidemic site in highland Ethiopia. Am J Trop Med Hyg (2011) 1.00
Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol (2005) 0.92
Lack of prediction of mefloquine and mefloquine-artesunate treatment outcome by mutations in the Plasmodium falciparum multidrug resistance 1 (pfmdr1) gene for P. falciparum malaria in Peru. Am J Trop Med Hyg (2003) 0.89
Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine (2008) 0.89
Endemic transmission of visceral leishmaniasis in Bhutan. Am J Trop Med Hyg (2012) 0.88
Virulence and disease in leishmaniasis: what is relevant for the patient? Trends Parasitol (2004) 0.86
Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008). Am J Trop Med Hyg (2011) 0.86
Evidence for a wide occurrence of proton-translocating pyrophosphatase genes in parasitic and free-living protozoa. Biochem Biophys Res Commun (2002) 0.86
Multilocus microsatellite typing revealed high genetic variability of Leishmania donovani strains isolated during and after a Kala-azar epidemic in Libo Kemkem district, northwest Ethiopia. Microbes Infect (2011) 0.85
Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev (2015) 0.85
Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Exp Parasitol (2010) 0.83
[Antiparasite therapy]. Enferm Infecc Microbiol Clin (2003) 0.82
The leishmaniasis e-compendium: a geo-referenced bibliographic tool. Trends Parasitol (2010) 0.81
Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. PLoS Med (2006) 0.81
Molecular epidemiology of cutaneous leishmaniasis in Venezuela. Trans R Soc Trop Med Hyg (2002) 0.80
Leishmania (Viannia) spp. dissemination and tissue tropism in naturally infected dogs (Canis familiaris). Trans R Soc Trop Med Hyg (2002) 0.79
The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg (2002) 0.78
Validation of the polymerase chain reaction for the diagnosis of human cutaneous leishmaniasis in north-west Colombia. Trans R Soc Trop Med Hyg (2002) 0.77
Homologous minicircles in Leishmania donovani. Trans R Soc Trop Med Hyg (2002) 0.76
Analysis of Kinetoplast DNA from Mexican Isolates of Leishmania (L.) mexicana. Interdiscip Perspect Infect Dis (2012) 0.75
Environmental Factors as Key Determinants for Visceral Leishmaniasis in Solid Organ Transplant Recipients, Madrid, Spain. Emerg Infect Dis (2017) 0.75
Genetic polymorphism of Plasmodium falciparum isolates from Loreto, Peru. Trans R Soc Trop Med Hyg (2002) 0.75
Comparative allele distribution at 16 STR loci between the Andean and coastal population from Peru. Forensic Sci Int Genet (2009) 0.75